FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $7,754,000 | +32.4% | 200,000 | 0.0% | 0.64% | -11.4% |
Q4 2021 | $5,856,851 | -1.3% | 200,000 | 0.0% | 0.72% | -12.1% |
Q3 2021 | $5,932,927 | -31.7% | 200,000 | 0.0% | 0.82% | -33.3% |
Q2 2021 | $8,687,679 | +5.3% | 200,000 | 0.0% | 1.24% | -4.2% |
Q1 2021 | $8,253,245 | -9.3% | 200,000 | 0.0% | 1.29% | -10.9% |
Q4 2020 | $9,102,093 | – | 200,000 | – | 1.45% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |